These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21435189)

  • 21. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
    Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
    Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
    BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
    Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
    Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JAK2 V617F mutation and thrombosis.
    Austin SK; Lambert JR
    Br J Haematol; 2008 Nov; 143(3):307-20. PubMed ID: 19004076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
    Levraut M; Legros L; Drappier C; Béné MC; Queyrel V; Raynaud S; Martis N
    J Thromb Thrombolysis; 2020 Nov; 50(4):995-1003. PubMed ID: 32266587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splanchnic vein thrombosis in myeloproliferative neoplasms.
    Sekhar M; McVinnie K; Burroughs AK
    Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The JAK2 V617F mutation in patients with cerebral venous thrombosis.
    Passamonti SM; Biguzzi E; Cazzola M; Franchi F; Gianniello F; Bucciarelli P; Pietra D; Mannucci PM; Martinelli I
    J Thromb Haemost; 2012 Jun; 10(6):998-1003. PubMed ID: 22469236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
    Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
    Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
    Owens CD
    J Vasc Surg; 2010 Jul; 52(1):205-7. PubMed ID: 20434300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of risk factors for thromboembolism in patients with JAK2
    Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
    [No Abstract]   [Full Text] [Related]  

  • 36. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of the JAK2 V617F Mutation in Urinary Cell-free DNA in Patients with Myeloproliferative Neoplasms.
    Hosoi H; Hori Y; Fukutsuka K; Osuga M; Koh Y; Mushino T; Hanaoka N; Yamamoto N; Ohno H; Sonoki T
    Intern Med; 2024 Jul; 63(14):1987-1993. PubMed ID: 38008450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.
    González-Montero J; Del Valle-Batalla L; Castillo-Astorga R; Marín Valdés A; Conte Lanza G
    Int J Lab Hematol; 2020 Jun; 42(3):331-334. PubMed ID: 32154655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.